A comparison of depot and oral atypical antipsychotics in terms of metabolic syndrome markers


Creative Commons License

Aykut D. S. , Karaguzel E. O.

PSYCHIATRY AND CLINICAL PSYCHOPHARMACOLOGY, cilt.28, ss.285-290, 2018 (SCI İndekslerine Giren Dergi) identifier identifier

  • Cilt numarası: 28 Konu: 3
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1080/24750573.2017.1414575
  • Dergi Adı: PSYCHIATRY AND CLINICAL PSYCHOPHARMACOLOGY
  • Sayfa Sayıları: ss.285-290

Özet

OBJECTIVES: The duration of life of patients with schizophrenia is shorter than that of the general population for various reasons. Especially cardiovascular diseases are one of the most important causes of death in patients with schizophrenia. Our aim in this study is comparison of second-generation depot antipsychotics and second-generation oral antipsychotics used in the treatment of patients with schizophrenia in terms of metabolic syndrome criteria.